A phase Ib/II trial of SGN-LIV1A in combination with pembrolizumab as first line treatment for locally advanced and metastatic TNBC

Trial Profile

A phase Ib/II trial of SGN-LIV1A in combination with pembrolizumab as first line treatment for locally advanced and metastatic TNBC

Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; SGN LIV1A (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top